MX2021004215A - Combinaciones de inhibidores de la replicación del virus de la gripe. - Google Patents

Combinaciones de inhibidores de la replicación del virus de la gripe.

Info

Publication number
MX2021004215A
MX2021004215A MX2021004215A MX2021004215A MX2021004215A MX 2021004215 A MX2021004215 A MX 2021004215A MX 2021004215 A MX2021004215 A MX 2021004215A MX 2021004215 A MX2021004215 A MX 2021004215A MX 2021004215 A MX2021004215 A MX 2021004215A
Authority
MX
Mexico
Prior art keywords
combinations
inhibitors
influenza virus
virus replication
influenza
Prior art date
Application number
MX2021004215A
Other languages
English (en)
Inventor
Irina C Jacobson
Biing Yuan Lin
Sam Sk Lee
Original Assignee
Cocrystal Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cocrystal Pharma Inc filed Critical Cocrystal Pharma Inc
Publication of MX2021004215A publication Critical patent/MX2021004215A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

En la presente se proporcionan combinaciones de compuestos que pueden inhibir la replicación de los virus de la gripe, reducir la cantidad de virus de la gripe y/o tratar la gripe.
MX2021004215A 2018-10-17 2019-10-17 Combinaciones de inhibidores de la replicación del virus de la gripe. MX2021004215A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862746884P 2018-10-17 2018-10-17
PCT/US2019/056632 WO2020081751A1 (en) 2018-10-17 2019-10-17 Combinations of inhibitors of influenza virus replication

Publications (1)

Publication Number Publication Date
MX2021004215A true MX2021004215A (es) 2021-07-15

Family

ID=68503202

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004215A MX2021004215A (es) 2018-10-17 2019-10-17 Combinaciones de inhibidores de la replicación del virus de la gripe.

Country Status (17)

Country Link
US (1) US20210353629A1 (es)
EP (1) EP3866778B1 (es)
JP (1) JP2022505183A (es)
KR (1) KR20210080413A (es)
CN (1) CN112969457A (es)
AU (1) AU2019361038A1 (es)
BR (1) BR112021007275A2 (es)
CA (1) CA3115823A1 (es)
DK (1) DK3866778T3 (es)
ES (1) ES2939148T3 (es)
FI (1) FI3866778T3 (es)
IL (1) IL282018A (es)
MX (1) MX2021004215A (es)
PL (1) PL3866778T3 (es)
PT (1) PT3866778T (es)
TW (1) TWI829785B (es)
WO (1) WO2020081751A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023527798A (ja) * 2020-05-23 2023-06-30 リミテッド・ライアビリティ・カンパニー“クロミス” ＣＯＶＩＤ－１９（ＳＡＲＳ－ＣｏＶ－２）を含むＲＮＡウイルス感染を治療するための方法
WO2022074630A1 (en) * 2020-10-09 2022-04-14 Auxilla Pharmaceuticals And Research Llp Liquid oral suspension of favipiravir
CN113413365B (zh) * 2021-07-30 2022-11-22 合肥医工医药股份有限公司 一种稳定的法维拉韦口服溶液制剂及其制备方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4180646A (en) 1975-01-28 1979-12-25 Alza Corporation Novel orthoester polymers and orthocarbonate polymers
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4131648A (en) 1975-01-28 1978-12-26 Alza Corporation Structured orthoester and orthocarbonate drug delivery devices
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
US4304767A (en) 1980-05-15 1981-12-08 Sri International Polymers of di- (and higher functionality) ketene acetals and polyols
US4353656A (en) 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
GR79615B (es) 1982-10-08 1984-10-31 Glaxo Group Ltd
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US4753788A (en) 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
US4811731A (en) 1985-07-30 1989-03-14 Glaxo Group Limited Devices for administering medicaments to patients
US4946931A (en) 1989-06-14 1990-08-07 Pharmaceutical Delivery Systems, Inc. Polymers containing carboxy-ortho ester and ortho ester linkages
AU6909091A (en) 1989-12-05 1991-06-26 Ramsey Foundation Neurologic agents for nasal administration to the brain
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6413536B1 (en) 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5968543A (en) 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US6956021B1 (en) 1998-08-25 2005-10-18 Advanced Inhalation Research, Inc. Stable spray-dried protein formulations
US6596296B1 (en) 1999-08-06 2003-07-22 Board Of Regents, The University Of Texas System Drug releasing biodegradable fiber implant
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
US7252840B1 (en) 1999-08-25 2007-08-07 Advanced Inhalation Research, Inc. Use of simple amino acids to form porous particles
US6749835B1 (en) 1999-08-25 2004-06-15 Advanced Inhalation Research, Inc. Formulation for spray-drying large porous particles
US6632666B2 (en) 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
US6613355B2 (en) 2000-05-11 2003-09-02 A.P. Pharma, Inc. Semi-solid delivery vehicle and pharmaceutical compositions
AU2001283546A1 (en) 2000-08-14 2002-02-25 Advanced Inhalation Research, Inc. Inhalation device and method
CA2433335C (en) 2000-12-29 2010-04-20 Advanced Inhalation Research, Inc. Particles for inhalation having sustained release properties
US6766799B2 (en) 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6848197B2 (en) 2001-04-18 2005-02-01 Advanced Inhalation Research, Inc. Control of process humidity to produce large, porous particles
US6524606B1 (en) 2001-11-16 2003-02-25 Ap Pharma, Inc. Bioerodible polyorthoesters containing amine groups
US7182961B2 (en) 2001-11-20 2007-02-27 Advanced Inhalation Research, Inc. Particulate compositions for pulmonary delivery
US7008644B2 (en) 2002-03-20 2006-03-07 Advanced Inhalation Research, Inc. Method and apparatus for producing dry particles
WO2005023335A2 (en) 2003-09-05 2005-03-17 Kurve Technology, Inc. Integrated nebulizer and particle dispersing chamber for delivery of medicament
SG11201804348SA (en) * 2015-12-15 2018-06-28 Shionogi & Co Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
WO2018127096A1 (en) * 2017-01-05 2018-07-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
WO2018157830A1 (en) * 2017-03-02 2018-09-07 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
EP3615545B1 (en) * 2017-04-24 2021-09-01 Cocrystal Pharma, Inc. Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication

Also Published As

Publication number Publication date
BR112021007275A2 (pt) 2021-07-20
CA3115823A1 (en) 2020-04-23
TWI829785B (zh) 2024-01-21
US20210353629A1 (en) 2021-11-18
ES2939148T3 (es) 2023-04-19
DK3866778T3 (da) 2023-02-20
WO2020081751A1 (en) 2020-04-23
JP2022505183A (ja) 2022-01-14
PT3866778T (pt) 2023-02-28
IL282018A (en) 2021-05-31
AU2019361038A1 (en) 2021-05-13
FI3866778T3 (fi) 2023-03-21
CN112969457A (zh) 2021-06-15
KR20210080413A (ko) 2021-06-30
EP3866778B1 (en) 2022-11-30
TW202024090A (zh) 2020-07-01
PL3866778T3 (pl) 2023-03-27
EP3866778A1 (en) 2021-08-25

Similar Documents

Publication Publication Date Title
MX2021006154A (es) Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
PH12018500899A1 (en) Compositions and methods for inhibiting arginase activity
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
MX2022000453A (es) Compuestos útiles para tratar infecciones por virus de influenza.
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
MA40404A (fr) Polythérapie pour traiter un paramyxovirus
MX2017012738A (es) Inhibidores de indolamina 2.3-dioxigenasa (ido) para el tratamiento de cancer.
CL2016001715A1 (es) Nuevos inhibidores de glutaminasa
WO2020055858A8 (en) Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
EA201992329A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201890723A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге
EA201791614A1 (ru) Производные индола в качестве ингибиторов репликации вирусов денге
EA201992334A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2021004215A (es) Combinaciones de inhibidores de la replicación del virus de la gripe.
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
MX2017011655A (es) Compuestos de aza-piridona y usos de estos.
CL2017003309A1 (es) Métodos de purificación y/o inactivación viral
ZA202102702B (en) Synergistic disinfectant compositions having enhanced antimicrobial efficacy and stability, and methods of using the same
MX2021006326A (es) Inhibidores de pcna.
PH12017550047B1 (en) Use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus
MX2016009597A (es) Terapias para el influenzavirus a subtipo h7n9.